Plasma ANXA6 levels were higher in patients with AIS (1.969 [1.228–3.086]) compared to healthy controls (1.249 [0.757–2.226]) (p < 0.001), that served as an independent risk factor for poor AIS outcomes (2.120 [1.563–3.023], p < 0.001). The gene discussed is ANXA6; the disease is androgen insensitivity syndrome.